These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10527002)

  • 1. Repeated significance tests on accumulating survival data.
    Skovlund E
    J Clin Epidemiol; 1999 Nov; 52(11):1083-8. PubMed ID: 10527002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of logrank tests and group sequential methods at fixed calendar times.
    DeMets DL; Gail MH
    Biometrics; 1985 Dec; 41(4):1039-44. PubMed ID: 4096915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A general formulation for a one-sided group sequential design.
    Moser BK; George SL
    Clin Trials; 2005; 2(6):519-28. PubMed ID: 16422312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
    Derks MGM; Blok EJ; Seynaeve C; Nortier JWR; Kranenbarg EM; Liefers GJ; Putter H; Kroep JR; Rea D; Hasenburg A; Markopoulos C; Paridaens R; Smeets JBE; Dirix LY; van de Velde CJH
    Lancet Oncol; 2017 Sep; 18(9):1211-1220. PubMed ID: 28732650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim analyses of survival data in cancer clinical trials.
    Skovlund E
    Acta Oncol; 1998; 37(7-8):645-50. PubMed ID: 10050981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim monitoring of sequential multiple assignment randomized trials using partial information.
    Manschot C; Laber E; Davidian M
    Biometrics; 2023 Dec; 79(4):2881-2894. PubMed ID: 36896962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
    Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update of the BIG 1-98 Trial: where do we stand?
    Joerger M; Thürlimann B
    Breast; 2009 Oct; 18 Suppl 3():S78-82. PubMed ID: 19914548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of group sequential logrank tests in a maximum duration trial.
    Lan KK; Lachin JM
    Biometrics; 1990 Sep; 46(3):759-70. PubMed ID: 2242413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
    Tjan-Heijnen VCG; van Hellemond IEG; Peer PGM; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; De Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Boer M; de Roos WK; Linn SC; Imholz ALT; Seynaeve CM;
    Lancet Oncol; 2017 Nov; 18(11):1502-1511. PubMed ID: 29031778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Bayesian with group sequential methods for monitoring clinical trials.
    Freedman LS; Spiegelhalter DJ
    Control Clin Trials; 1989 Dec; 10(4):357-67. PubMed ID: 2691203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: an update based on 10 years' follow-up. German Breast Cancer Study Group.
    Sauerbrei W; Bastert G; Bojar H; Beyerle C; Neumann RL; Schmoor C; Schumacher M
    J Clin Oncol; 2000 Jan; 18(1):94-101. PubMed ID: 10623698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential interim analyses of survival data in DNA microarray experiments.
    Leha A; Beissbarth T; Jung K
    BMC Bioinformatics; 2011 Apr; 12():127. PubMed ID: 21527044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A parametric model for long-term follow-up data from phase III breast cancer clinical trials.
    Jeong JH; Jung SH; Wieand S
    Stat Med; 2003 Feb; 22(3):339-52. PubMed ID: 12529867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
    van de Velde CJ; Rea D; Seynaeve C; Putter H; Hasenburg A; Vannetzel JM; Paridaens R; Markopoulos C; Hozumi Y; Hille ET; Kieback DG; Asmar L; Smeets J; Nortier JW; Hadji P; Bartlett JM; Jones SE
    Lancet; 2011 Jan; 377(9762):321-31. PubMed ID: 21247627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer.
    Ryan PD; Goss PE
    Nat Clin Pract Oncol; 2005 Dec; 2(12):596-7. PubMed ID: 16341095
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.